Company intelligence / Profile preview
SonoThera
South San Francisco, California, United Statessonothera.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
SonoThera has demonstrated preclinical proof-of-concept for its ultrasound-guided, microbubble-mediated nonviral gene delivery technology. No human clinical results have been reported yet. The company aims to initiate first-in-human studies in 2025.
- Therapeutic areas
- Nephrology
- Modalities
- Gene therapyNonviral gene therapy (microbubble-mediated)Nucleic acid-based drugs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
GE HealthCare (exclusive licensing of Optison® and Sonazoid® microbubble products for use with SonoThera’s platform)
Beyond the preview
Go deeper on SonoThera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SonoThera.